Zyversa Therapeutics, Inc.

    • Market Cap $1.11M
    • PE -0
    • Debt $NaN
    • Cash $119.49K
    • EV $NaN
    • FCF $NaN

    Earnings

    loading chart...

    Sales & Net Margins

    loading chart...
    Earnings-$21.86M
    EBIT-$22.42M
    ROE-254%
    ROA-115%
    Equity$8.62M
    Growth Stability1
    PE-0.05
    PB0.13
    Price/Cash0.11
    Equity CAGR-45%
    Earnings Growth YoY-97%
    Earnings Growth QoQ-2%
    Equity CAGR 5Y-45%
    Equity CAGR 3Y-69%
    Market Cap$1.11M
    Assets$19.47M
    Cash$119.49K
    Shares Outstanding728.88K
    Working Capital-9.35M
    Current Ratio0.06
    Shares Growth 3y178%
    Equity Growth QoQ-23%
    Equity Growth YoY-57%

    Assets & ROA

    loading chart...

    Stockholders Equity & ROE

    loading chart...
    ZyVersa Therapeutics Inc is a clinical stage specialty biopharmaceutical company that leverages advanced proprietary technologies to develop and commercialize first-in-class prescription drugs. The company's focus is on restoring health and improving quality of life for patients with high unmet medical needs, with emphasis on inflammatory and renal diseases.

    SEC Filings

    Direct access to Zyversa Therapeutics, Inc. (ZVSA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

    • 2024
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2023
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31
    • 2022
      • 10-K Dec 31
      • 10-Q Sep 30
      • 10-Q Jun 30
      • 10-Q Mar 31

    Sector Comparison

    How does Zyversa Therapeutics, Inc. compare to its competitors?

    Loading chart...

    Peter Lynch's Chart

    This chart shows the current pricing of Zyversa Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

    loading chart...

    Zyversa Therapeutics, Inc. Discounted Cash Flow

    Fully customizable DCF calculator online for Zyversa Therapeutics, Inc..

    0
    012345678910TV
    fcf$0$0$0$0$0$0$0$0$0$0$0$0
    DCF$0$0$0$0$0$0$0$0$0$0$0
    Value$0

    Competitiveness and MOAT

    High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

    Years03/202112/202212/2023TTM
    Net Margins----
    ROA--1%-487%-115%
    ROE--0%-959%-254%

    Safety and Stability

    Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

    Years03/202112/202212/2023TTM
    Debt over FCF----
    Debt over Equity----
    Growth Stability---1

    Growth

    Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

    Years03/202112/202212/2023CAGR 5Y
    Revenue YoY growth----
    Earnings YoY growth-7K%142K%-
    Equity YoY growth--23M%-89%-45%
    FCF YoY growth----